How does NTRK fusion affect Breast Cancer treatment options

NTRK Fusion and Breast Cancer Treatment Options

What is NTRK Fusion?

NTRK gene fusions are rare genetic changes found in about 1% of all solid tumors, including breast cancer. These fusions occur when the NTRK gene (which encodes proteins called TRK) becomes abnormally joined with another gene. This creates a protein that can drive cancer cell growth.

How Doctors Approach NTRK-Positive Breast Cancer

When an NTRK fusion is detected in breast cancer, oncologists recognize this as a targetable biomarker—meaning there are specific drugs designed to attack this particular genetic change. According to NCCN Guidelines for Invasive Breast Cancer, this finding opens up targeted therapy options that wouldn't otherwise be considered.

Treatment Options Available

If you have an NTRK fusion-positive breast cancer, three FDA-approved targeted therapies are recommended:

1. Larotrectinib

• Targets TRK proteins encoded by NTRK1, NTRK2, and NTRK3 genes
• Category 2A recommendation (other recommended regimen)
• Indicated for solid tumors with NTRK fusions that have progressed on prior treatment or have no satisfactory alternative options

2. Entrectinib

• Also targets TRK proteins
• Category 2A recommendation
• Similar indication as larotrectinib

3. Repotrectinib

• A newer TRK inhibitor granted FDA accelerated approval
• Category 2A recommendation (useful in certain circumstances)
• Can be used in first-line or subsequent therapy settings

Clinical Evidence

Research shows these drugs work effectively for NTRK fusion-positive tumors:

• Larotrectinib: In long-term follow-up of 153 patients, 79% achieved objective response (cancer shrinkage), with a median progression-free survival of 28.3 months
• Entrectinib: In 121 patients at median follow-up of 25.8 months, 61% had complete or partial responses, with median duration of response of 20 months

Important Context

According to NCCN Guidelines, these targeted therapies are recommended for:

• Patients whose cancer has progressed following prior treatment, OR
• Patients who have no satisfactory alternative treatment options

This means your oncologist will determine whether a TRK inhibitor is appropriate based on your complete clinical picture, including what treatments you've already received and what other options are available.

Questions to Ask Your Oncologist

If you've been found to have an NTRK fusion, consider asking:

1. "Is my NTRK fusion confirmed by the most sensitive testing method?" (RNA-based NGS is considered optimal for detecting NTRK fusions)

2. "Which TRK inhibitor do you recommend for my specific situation—larotrectinib, entrectinib, or repotrectinib—and why?"

3. "When would you recommend starting this therapy relative to my other treatment options?"

4. "What side effects should I monitor for, and how will we track whether the drug is working?"

5. "Are there clinical trials available for NTRK-positive breast cancer that I should consider?"

Key Takeaway

Finding an NTRK fusion in your breast cancer is actually good news from a treatment perspective because it identifies a specific vulnerability that targeted drugs can exploit. However, your oncologist will determine the best timing and approach based on your individual case, other biomarkers, and treatment history.

---

Sources cited:

• NCCN Guidelines for Invasive Breast Cancer (Version 5.2025)
• NCCN Guidelines for Patients: Metastatic Breast Cancer (2024)

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.